Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 4007-4011

  Shao, Y U Yun ^a,b   Chen, Pei Jer ^a,b   Lin, Zhong Zhe ^a   Huang, Chien Chung ^a   Ding, Yea Hui ^a   Lee, Ying Hui ^a   Hsu, Chih Hung ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antiangiogenic therapy; Hepatitis B virus; Hepatocellular carcinoma; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; SORAFENIB; THALIDOMIDE; UFT; VIRUS DNA;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS DETECTION;

EID: 84984552696     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bosch FX, Ribes J, Diaz M and Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16, 2004. (Pubitemid 39423365)
2. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH and Cheng AL: Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116: 4590-4596, 2010.
3. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C and Cheng AL: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53: 126-131, 2010.
4. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY and Cheng AL: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 102: 981-986, 2010.
5. Hsu C, Chang D, Lin Z, Lee K, Hsiao C, Shen Y, Cheng A and Hsu C: Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study. J Clin Oncol 26 suppl: abstr 15598, 2008.
6. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, and Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73, 2006. (Pubitemid 43042691)
7. Chan HL, Wong VW, Wong GL, Chim AM, Lai LH and Sung JJ: Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol 47: 1830-1836, 2009.
8. Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S and Asaka M: The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 44: 991-999, 2009.
9. Huang Y, Wang Z, An S, Zhou B, Zhou Y, Chan HL and Hou J: Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 80: 591-597, 2008. (Pubitemid 351358554)
10. Hung IF, Poon RT, Lai CL, Fung J, Fan ST and Yuen MF: Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 103: 1663-1673, 2008.
11. Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, Kim CW, Nam SW, Cho SH, Yang JM and Lee CD: The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer 110: 1760-1767, 2007.
12. Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, Mok TS, Lam KC, Ho WM, Koh J, Tang JW, Chan AT and Chan PK: Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 45: 1382-1389, 2007. (Pubitemid 46918322)
13. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS and Chen PJ: Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 41: 659-666, 2004. (Pubitemid 39297803)
17. The Cancer of the Liver Italian Program (CLIP) investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28: 751-755, 1998.
18. Llovet JM, Bru C and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.